Cagrilintide
AM-833, Long-acting amylin analogue
A long-acting amylin receptor agonist used for obesity and type 2 diabetes treatment by enhancing satiety, reducing food intake, and aiding weight loss.
Recruiting
PHASE1
NCT06719011
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT07220642
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE1
NCT06144684
A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295
AbbVie
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT05564104
A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT05804162
A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT06289504
A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06323174
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT03600480
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT05996848
A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06780449
A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE3
NCT07220759
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06131437
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE1
NCT06267092
A Study of How CagriSema Works on Appetite in People With Excess Body Weight
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT03787225
A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06388187
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE1
NCT04940078
A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE2
NCT06409130
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06065540
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE3
NCT07282613
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT06131372
A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025